Trial Profile
Safe Stop Trial: observational study of the STOP & GO strategy of PD-1 blockade in advanced melanoma patients upon achieving a complete (CR) or partial response (PR)
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Proof of concept; Therapeutic Use
- Acronyms Safe Stop Trial
- 25 Mar 2021 Trial design published in the BMC Cancer.
- 15 Oct 2018 New trial record